Page last updated: 2024-11-02

oxidopamine and Autism Spectrum Disorder

oxidopamine has been researched along with Autism Spectrum Disorder in 1 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)

Research Excerpts

ExcerptRelevanceReference
"Cannabidivarin (CBDV), a structural analog of cannabidiol (CBD), has received attention in recent years owing to its anticonvulsant property and potential for treating autism spectrum disorder."4.31Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans. ( Jin, S; Jin, T; Li, H; Liu, C; Liu, Y; Long, H; Lu, Y; Peng, Y; Wang, F; Wang, X; Zhao, L, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Wang, F1
Jin, T1
Li, H1
Long, H1
Liu, Y1
Jin, S1
Lu, Y1
Peng, Y1
Liu, C1
Zhao, L1
Wang, X1

Other Studies

1 other study available for oxidopamine and Autism Spectrum Disorder

ArticleYear
Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2023, Volume: 37, Issue:2

    Topics: alpha-Synuclein; Animals; Autism Spectrum Disorder; Caenorhabditis elegans; Caenorhabditis elegans P

2023